PRER14C

PRELIMINARY INFORMATION STATEMENT – SUBJECT TO COMPLETION

PPD, Inc.

929 North Front Street

Wilmington, North Carolina 28401

The following information is being provided to amend PPD Inc.’s (the “Company”) preliminary information statement filed with the Securities and Exchange Commission on May 14, 2021 (the “information statement”). Text that is bold and struck through in the disclosures below shows text being removed from those disclosures and text that is bold and underlined below shows text being added to those disclosures. Terms used but not otherwise defined herein have the meanings given to them in the information statement, and all references to captions and page numbers refer to captions and page numbers in the information statement, respectively, unless otherwise provided.

Except as otherwise set forth below, the information set forth in the information statement remains unchanged and is incorporated by reference as relevant to the items in this Amendment No. 1 to the information statement.

THE INFORMATION STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION AND THIS AMENDMENT SHOULD BE READ IN CONJUNCTION WITH THE INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

1. The first paragraph in the section entitled “Summary—Regulatory Approvals (page 43)” on page 7 of the information statement is amended and restated in its entirety as follows:

Under the HSR Act and related rules, certain transactions, including the Merger, may not be completed until notifications have been given and information furnished to the Antitrust Division of the United States Department of Justice (“Antitrust Division”) and the Federal Trade Commission (“FTC”) and all statutory waiting period requirements have been satisfied or early termination has been granted by the applicable agencies. On ~~April~~ May 13, 2021, both the Company and Thermo Fisher filed their respective notification and report forms under the HSR Act.

2. The second paragraph in the section entitled “The Merger—Regulatory Approvals” on page 43 of the information statement is amended and restated in its entirety as follows:

Under the HSR Act and related rules, certain transactions, including the Merger, may not be completed until notifications have been given and information furnished to the Antitrust Division and the FTC and all statutory waiting period requirements have been satisfied or early termination has been granted by the applicable agencies. On ~~April~~ May 13, 2021, both the Company and Thermo Fisher filed their respective notification and report forms under the HSR Act and requested early termination of the initial 30-day waiting period under the HSR Act.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements, and other documents with the SEC. These reports contain additional information about the Company. Stockholders may read and copy any reports, statements or other information filed by the Company at the SEC’s Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of this information by mail from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates. Please call the SEC at (800) SEC-0330 for further information on the operation of the Public Reference Room. The Company’s SEC filings are made electronically available to the public at the SEC’s website located at www.sec.gov. Stockholders can also obtain free copies of our SEC filings through the “Investor Relations” section of the Company’s website at https://investors.ppd.com/investor-relations. Our website address is being provided as an inactive textual reference only. The information provided on, or accessible through, our website, other than the copies of the documents listed or referenced in the information statement that have been or will be filed with the SEC, is not part of the information statement, as amended, and therefore is not incorporated herein by reference.

The Company undertakes to provide without charge to each person to whom a copy of the information statement, as amended, has been delivered, upon written or oral request, by first class mail or other equally prompt means within one business day of receipt of such request, a copy of any or all of the documents incorporated by reference in the information statement, as amended, other than the exhibits to these documents, unless the exhibits are specifically incorporated by reference into the information that the information statement, as amended, incorporates. You may request a copy of these filings by telephone at (910) 251-0081 or by writing to us at:

Investor Relations

929 North Front Street

Wilmington, NC 28401

e-mail: Investors@ppd.com

Thermo Fisher and Merger Sub have supplied, and the Company has not independently verified, the information in the information statement, as amended, relating to Thermo Fisher and Merger Sub.

Stockholders should not rely on information that purports to be made by or on behalf of the Company other than that contained in or incorporated by reference in the information statement, as amended. The Company has not authorized anyone to provide information on behalf of the Company that is different from that contained in the information statement, as amended. This Amendment No. 1 to the information statement is dated , 2021. No assumption should be made that the information contained in the information statement, as amended, is accurate as of any date other than that date, and the mailing of the information statement, as amended, will not create any implication to the contrary.


☒		Preliminary information statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))

☐		Definitive information statement



☐	No fee required.

☐	Fee computed below per Exchange Act Rules 14c-5(g) and 0-11

	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
☒	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount Previously Paid:
	2)	Form, Schedule or Registration Statement No.:
	3)	Filing Party:
	4)	Date Filed: